TYK2 and type 1 diabetes mellitus: Notwithstanding these unresolved questions, our results underscore the diverse and beneficial effects of TYK2 inhibition at the level of the β cell and the immune system in pre-clinical models of T1D, strongly supporting the rationale for testing these agents as a novel therapy to preserve β cells in T1D.